RecruitingPhase 4NCT06035757

The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery

The Effect of Administration of Sugammadex on the Occurrence of Emergence Agitation in Pediatric Strabismus Surgery-prospective Randomized Controlled Trial


Sponsor

Konkuk University Medical Center

Enrollment

76 participants

Start Date

Dec 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The present trial conducted to demonstrate the administration of sugammadex as reversal of neuromuscular blockade agent reduces the incidence of emergence agitation (EA) comparing to neostigmine


Eligibility

Min Age: 4 YearsMax Age: 7 Years

Inclusion Criteria1

  • Patients scheduled elective strabismus surgery aged 4-7 with American Society of Anesthesiologists (ASA) classification 1-3.

Exclusion Criteria6

  • ASA classification 3 or more
  • impaired liver function
  • impaired kidney function
  • myasthenia gravis or other neuromuscular disorders
  • history of drug allergy
  • cardiovascular disease or arrhythmia

Interventions

DRUGBridion 200 MG in 2 ML Injection

Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.

DRUGPyridostigmine Bromide 5 MG/ML

Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.


Locations(1)

Konkuk University Medical Center

Seoul, Seoul-T'ǔkpyǒlshi, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06035757


Related Trials